Jack Bendheim Sells 3,520 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 3,520 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $42.86, for a total transaction of $150,867.20. Following the completion of the transaction, the chief executive officer directly owned 58,880 shares of the company’s stock, valued at approximately $2,523,596.80. This trade represents a 5.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total value of $1,734,742.87.
• On Tuesday, November 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.10, for a total value of $151,712.00.
• On Thursday, October 30th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.07, for a total value of $144,566.40.
• On Tuesday, October 28th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.56, for a total value of $146,291.20.
• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.18, for a total value of $141,433.60.
• On Wednesday, October 22nd, Jack Bendheim sold 11,859 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.27, for a total value of $477,561.93.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50.
• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.03, for a total transaction of $28,021.00.
• On Thursday, September 18th, Jack Bendheim sold 7,022 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.26, for a total transaction of $282,705.72.
• On Wednesday, September 10th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.29, for a total transaction of $145,340.80.

Phibro Animal Health Stock Down 1.1%

PAHC opened at $45.33 on Wednesday. The firm has a market capitalization of $1.84 billion, a P/E ratio of 38.42, a price-to-earnings-growth ratio of 1.24 and a beta of 0.81. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $46.42. The company has a fifty day moving average price of $40.06 and a 200-day moving average price of $31.43. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The company had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be issued a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 1.1%. Phibro Animal Health’s payout ratio is presently 28.92%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PAHC shares. Bank of America raised their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, November 5th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a report on Thursday, August 28th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 29th. Finally, JPMorgan Chase & Co. raised their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and an average price target of $31.40.

Hedge Funds Weigh In On Phibro Animal Health

A number of large investors have recently added to or reduced their stakes in PAHC. Principal Financial Group Inc. boosted its position in Phibro Animal Health by 2.6% during the first quarter. Principal Financial Group Inc. now owns 101,356 shares of the company’s stock valued at $2,165,000 after buying an additional 2,573 shares during the period. Jackson Creek Investment Advisors LLC bought a new stake in shares of Phibro Animal Health in the 1st quarter valued at about $1,411,000. Hussman Strategic Advisors Inc. boosted its holdings in Phibro Animal Health by 20.0% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 126,000 shares of the company’s stock valued at $2,691,000 after acquiring an additional 21,000 shares during the period. Csenge Advisory Group grew its position in Phibro Animal Health by 26.4% during the 1st quarter. Csenge Advisory Group now owns 26,143 shares of the company’s stock worth $558,000 after acquiring an additional 5,456 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Phibro Animal Health in the 1st quarter worth approximately $331,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.